G1 Therapeutics (GTHX) Short Interest Ratio & Short Volume → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free GTHX Stock Alerts $4.10 -0.01 (-0.24%) (As of 04/22/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability G1 Therapeutics Short Interest DataCurrent Short Volume2,760,000 sharesPrevious Short Volume2,690,000 sharesChange Vs. Previous Month+2.60%Dollar Volume Sold Short$11.92 millionShort Interest Ratio / Days to Cover1.9Last Record DateMarch 31, 2024Outstanding Shares52,230,000 sharesPercentage of Shares Shorted5.28%Today's Trading Volume487,879 sharesAverage Trading Volume1,325,201 sharesToday's Volume Vs. Average37% Short Selling G1 Therapeutics ? Sign up to receive the latest short interest report for G1 Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatGTHX Short Interest Over TimeGTHX Days to Cover Over TimeGTHX Percentage of Float Shorted Over Time Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide G1 Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20242,760,000 shares $11.92 million +2.6%N/A1.9 $4.32 3/15/20242,690,000 shares $8.37 million -7.6%N/A1.9 $3.11 2/29/20242,910,000 shares $9.66 million -12.6%N/A1.5 $3.32 2/15/20243,330,000 shares $7.99 million +27.6%N/A1.8 $2.40 1/31/20242,610,000 shares $10.31 million -19.7%N/A1.8 $3.95 1/15/20243,250,000 shares $10.40 million +16.9%N/A2.4 $3.20 Get the Latest News and Ratings for GTHX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20232,780,000 shares $8.48 million +5.3%N/A2.2 $3.05 12/15/20232,640,000 shares $7.68 million +9.1%N/A2.3 $2.91 11/30/20232,420,000 shares $4.55 million -2.8%N/A3.1 $1.88 11/15/20232,490,000 shares $4.06 million +2.1%N/A4.8 $1.63 10/31/20232,440,000 shares $4.03 million -6.5%N/A4.4 $1.65 10/15/20232,610,000 shares $2.98 million -5.8%N/A3.4 $1.14 9/30/20232,770,000 shares $3.99 million -4.5%N/A3.4 $1.44 9/15/20232,900,000 shares $4.47 million -1.0%N/A3.5 $1.54 8/31/20232,930,000 shares $4.89 million No ChangeN/A3.3 $1.67 8/15/20232,930,000 shares $5.48 million -10.1%N/A3 $1.87 7/31/20233,260,000 shares $7.82 million +4.5%N/A3.2 $2.40 7/15/20233,120,000 shares $7.52 million +1.0%N/A3.6 $2.41 6/30/20233,090,000 shares $7.69 million +20.2%N/A3.9 $2.49 6/15/20232,570,000 shares $7.27 million -13.2%N/A3.1 $2.83 5/31/20232,960,000 shares $7.52 million -5.1%N/A3.3 $2.54 5/15/20233,120,000 shares $9.11 million -5.7%N/A3.3 $2.92 4/30/20233,310,000 shares $9.50 million -12.4%N/A2.8 $2.87 4/15/20233,780,000 shares $10.02 million -10.2%N/A3.2 $2.65 3/31/20234,210,000 shares $11.28 million +14.7%N/A3.4 $2.68 3/15/20233,670,000 shares $12.00 million +28.3%N/A2.9 $3.27 2/28/20232,860,000 shares $10.35 million -6.2%N/A2.2 $3.62 2/15/20233,050,000 shares $11.19 million -2.2%N/A2.3 $3.67 1/31/20233,120,000 shares $24.90 million +1.0%N/A2.7 $7.98 1/15/20233,090,000 shares $19.53 million +20.2%N/A2.7 $6.32 12/30/20222,570,000 shares $13.96 million -46.1%N/A2.3 $5.43 12/15/20224,770,000 shares $29.67 million +5.8%N/A4.3 $6.22 11/30/20224,510,000 shares $26.88 million -26.8%10.9%4 $5.96 11/15/20226,160,000 shares $55.01 million -18.2%14.9%6 $8.93 10/31/20227,530,000 shares $80.27 million +7.0%21.5%8.5 $10.66 10/15/20227,040,000 shares $78.21 million +9.7%20.2%7.3 $11.11 9/30/20226,420,000 shares $80.19 million +65.9%18.4%6.2 $12.49 9/15/20223,870,000 shares $59.79 million +11.9%11.1%3.5 $15.45 8/31/20223,460,000 shares $50.20 million -8.0%9.9%3 $14.51 8/15/20223,760,000 shares $49.26 million -20.7%10.8%3.1 $13.10Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him GTHX Short Interest - Frequently Asked Questions What is G1 Therapeutics' current short interest? Short interest is the volume of G1 Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 2,760,000 shares of GTHX short. Learn More on G1 Therapeutics' current short interest. What is a good short interest ratio for G1 Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GTHX shares currently have a short interest ratio of 2.0. Learn More on G1 Therapeutics's short interest ratio. Which institutional investors are shorting G1 Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of G1 Therapeutics: Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is G1 Therapeutics' short interest increasing or decreasing? G1 Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,760,000 shares, an increase of 2.6% from the previous total of 2,690,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does G1 Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to G1 Therapeutics: Abeona Therapeutics Inc (7.73%), Galectin Therapeutics Inc. (5.31%), Design Therapeutics, Inc. (6.75%), Generation Bio Co. (2.35%), Zevra Therapeutics, Inc. (5.63%), NuCana plc (0.35%), Ovid Therapeutics Inc. (4.78%), uniQure (5.83%), Conduit Pharmaceuticals Inc. (0.53%), Skye Bioscience, Inc. (0.29%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short G1 Therapeutics stock? Short selling GTHX is an investing strategy that aims to generate trading profit from G1 Therapeutics as its price is falling. GTHX shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against G1 Therapeutics? A short squeeze for G1 Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GTHX, which in turn drives the price of the stock up even further. How often is G1 Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GTHX, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Abeona Therapeutics Short Squeeze Galectin Therapeutics Short Squeeze Design Therapeutics Short Squeeze Generation Bio Short Squeeze Zevra Therapeutics Short Squeeze NuCana Short Squeeze Ovid Therapeutics Short Squeeze uniQure Short Squeeze Conduit Pharmaceuticals Short Squeeze Skye Bioscience Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GTHX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press